Oncology
[Oncology archives]

1. Dluzniewski PJ, Wang MH, Zheng SL, De Marzo AM, Drake CG, Fedor HL, Partin AW, Han M, Fallin MD, Xu J, Isaacs WB, Platz EA. Variation in IL10 and other genes involved in the immune response and in oxidation and prostate cancer recurrence. Cancer Epidemiol Biomarkers Prev. 2012 Oct;21(10):1774-82. doi: 10.1158/1055-9965.EPI-12-0458. Epub 2012 Aug 2.
Key words: IL10, prostate cancer, recurrence
http://www.ncbi.nlm.nih.gov/pubmed/22859398

2. Huo JS, Zambidis ET. Pivots of pluripotency: The roles of non-coding RNA in regulating embryonic and induced pluripotent stem cells. Biochim Biophys Acta. 2012 Oct 24. doi:pii: S0304-4165(12)00300-5. 10.1016/j.bbagen.2012.10.014. [Epub ahead of print]
Key words: RNA, stem cells, pluripotent
http://www.ncbi.nlm.nih.gov/pubmed/23104383

3. Isaacs JT, D'Antonio JM, Chen S, Antony L, Dalrymple SP, Ndikuyeze GH, Luo J, Denmeade SR. Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer. Prostate. 2012 Oct 1;72(14):1491-505. doi: 10.1002/pros.22504. Epub 2012 Mar 6.
Key words: prostate cancer, BAT, paradigm shifting
http://www.ncbi.nlm.nih.gov/pubmed/22396319

4. Karp JE, Thomas BM, Greer JM, Sorge C, Gore SD, Pratz KW, Smith BD, Flatten K, Peterson KL, Schneider P, Mackey K, Freshwater T, Levis M, McDevitt M, Carraway HE, Gladstone DE, Showel MM, Loechner S, Parry DA, Horowitz JA, Issacs R, Kaufmann SH. Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias. Clin Cancer Res. 2012 Nov 12. [Epub ahead of print]
Key words: arabinoside, leukemia, cytosine
http://www.ncbi.nlm.nih.gov/pubmed/23092873

5. Mullins JK, Feng Z, Trock BJ, Epstein JI, Walsh PC, Loeb S. The impact of anatomical radical retropubic prostatectomy on cancer control: the 30-year anniversary. J Urol. 2012 Oct 18. doi:pii: S0022-5347(12)04485-0. 10.1016/j.juro.2012.08.028. [Epub ahead of print]
Key words: retropubic, prostatectomy
http://www.ncbi.nlm.nih.gov/pubmed/23083655

6. Raabe EH, Eberhart CG. Methylome alterations "mark" new therapeutic opportunities in glioblastoma. Cancer Cell. 2012 Oct 16;22(4):417-8. doi: 10.1016/j.ccr.2012.10.001.
Key words: methylome, glioblastoma
http://www.ncbi.nlm.nih.gov/pubmed/23079650

7. Ren YR, Chaerkady R, Hu S, Wan J, Qian J, Zhu H, Pandey A, Kern SE. Unbiased discovery of interactions at a control locus driving expression of the cancer-specific therapeutic and diagnostic target, mesothelin. J Proteome Res. 2012 Nov 2;11(11):5301-10. doi: 10.1021/pr300797v. Epub 2012 Oct 12.
Key words: mesothelin, control lucus
http://www.ncbi.nlm.nih.gov/pubmed/23025254

8. Rudin CM, Durinck S, Stawiski EW, Poirier JT, Modrusan Z, Shames DS, Bergbower EA, Guan Y, Shin J, Guillory J, Rivers CS, Foo CK, Bhatt D, Stinson J, Gnad F, Haverty PM, Gentleman R, Chaudhuri S, Janakiraman V, Jaiswal BS, Parikh C, Yuan W, Zhang Z, Koeppen H, Wu TD, Stern HM, Yauch RL, Huffman KE, Paskulin DD, Illei PB, Varella-Garcia M, Gazdar AF, de Sauvage FJ, Bourgon R, Minna JD, Brock MV, Seshagiri S. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet. 2012 Oct;44(10):1111-6. doi: 10.1038/ng.2405. Epub 2012 Sep 2.
Key words: lung cancer, SOX2, genomic analysis
http://www.ncbi.nlm.nih.gov/pubmed/22941189

9. Terezakis SA, Kasamon YL. Tailored strategies for radiation therapy in classical Hodgkin's lymphoma. Crit Rev Oncol Hematol. 2012 Oct;84(1):71-84. doi: 10.1016/j.critrevonc.2012.02.006.
Key words: Hodgkin's lymphoma, radiation therapy
http://www.ncbi.nlm.nih.gov/pubmed/22463873

Return to top of Publications - Oncology